Get the Daily Brief
Latest Biotech News
M&A: J&J buys Firefly to enter degrader-antibody conjugates
Johnson & Johnson will acquire Firefly Bio for $1 billion in cash, gaining access to Firefly’s “degrader antibody conjugates” platform. The deal is designed to complement J&J’s oncology pipeline...
M&A: Treeline goes public via reverse merger
Treeline Biosciences announced a definitive reverse-merger agreement with Standard BioTools, positioning the combined company to trade on Nasdaq under the TRLN ticker. Standard BioTools...
Partnering: Roche commits $700M for Nurix’s BTK degrader
Roche agreed to pay Nurix Therapeutics $700 million upfront to co-develop and co-commercialize the company’s bexobrutideg BTK degrader in B-cell malignancies. Under the terms, Roche will fund 60%...
Clinical: Tango/Revolution combo sets high early bar in PDAC
Tango Therapeutics’ vopimetostat plus Revolution Medicines’ daraxonrasib combination produced durable response signals in an early-stage study of metastatic pancreatic ductal adenocarcinoma with...
Regulatory: FDA clears Amphista’s BRD9 degrader for AML Phase I
Amphista Therapeutics received FDA IND clearance for AMX-883, an oral BRD9 degrader for acute myeloid leukemia. The company plans to start a Phase I trial in relapsed or refractory AML and...
Regulatory/oncology: Sonrotoclax wins FDA approval for mantle cell lymphoma
Sonrotoclax (Beqalzi®) received FDA approval in May 2026 for patients with mantle cell lymphoma who have tried at least two prior therapies, positioning the drug as the second Bcl-2 inhibitor...
Funding: City Therapeutics raises to expand RNAi pipeline beyond liver
City Therapeutics raised $99.5 million to advance clinical development of its first three RNAi medicines and expand into additional targets beyond the liver. The funding supports the company’s...
Platform/data: Lonza licensing deal expands Stipple Bio’s precision oncology ADC toolkit
Lonza entered a licensing agreement with Stipple Bio to provide the startup access to Lonza’s site-specific ADC technology platform across multiple programs. Stipple said the deal includes...
Drug discovery science: CRISPR “chromatin shredding” targets mutant p53 in tumors
Researchers engineered a CRISPR system designed to selectively trigger cancer cell death by “chromatin shredding” through recognition of mutant p53 mRNA, according to a new Nature study led by...
Johnson & Johnson expands targeted oncology with Firefly Bio acquisition
Johnson & Johnson will acquire Firefly Bio for $1 billion in cash, adding a new “degrader-antibody conjugate” (DAC) platform to its oncology pipeline. The deal gives J&J access to Firefly’s...
Roche and Nurix commit to BTK degrader race vs Lilly’s Jaypirca
Roche is paying Nurix Therapeutics $700 million upfront, with up to $2.3 billion in milestones, to secure rights and collaboration on bexobrutideg, a BTK degrader for B-cell malignancies. Roche...
Incyte doubles down on late-stage bleeding disorder assets via Vega Therapeutics buyout
Incyte will acquire Vega Therapeutics in a deal that could reach about $2.0 billion, with the acquisition aimed at adding a late-stage bleeding disorder medicine to its late-phase portfolio. The...
Treeline Biosciences pursues Nasdaq listing via reverse merger with Standard BioTools
Treeline Biosciences will go public through a reverse merger with Standard BioTools, with the combined company operating under the Treeline Biosciences name and trading on the Nasdaq as TRLN. The...
Precision oncology dealmaking: Lonza licensing agreement expands Stipple Bio ADC toolkit
Lonza and Stipple Bio struck a licensing agreement to expand Stipple’s precision oncology ADC capabilities. Under the pact, Lonza provides access to its site-specific ADC platform, including...
Pancreatic cancer gets a new momentum boost after Tango-Revolution combination response
Tango Therapeutics and Revolution Medicines reported that combining Tango’s vopimetostat with Revolution’s daraxonrasib produced durable responses in a small pancreatic cancer clinical study,...
Boehringer Ingelheim faces new Phase 3 tolerability scrutiny for survodutide
At the American Diabetes Association (ADA) 2026 Scientific Sessions, Boehringer Ingelheim executives said survodutide’s tolerability is consistent with the class while responding to new Phase 3...
Amphista’s BRD9 degrader clears IND for AML phase 1 start
Amphista Therapeutics received IND clearance from the FDA for AMX-883, an orally bioavailable BRD9 degrader intended for acute myeloid leukemia (AML). The company expects a phase 1 trial to begin...
Neurodegeneration biology links sleep/circadian disruption to Parkinson’s clearance defects
Researchers tied sleep and circadian disruption to impaired brain clearance mechanisms relevant to Parkinson’s disease. The work, led by Zafar and Schneider and slated for publication in npj...
Ionis’ zilganersen faces FDA decision after pivotal Alexander disease trial misses secondary endpoints
Ionis Pharmaceuticals is awaiting an FDA decision for zilganersen (an antisense oligonucleotide) after a pivotal Phase I–III study in Alexander disease missed secondary endpoints. The trial...
BTK degraders: Roche’s bet pressures Lilly’s established lead
Roche is paying Nurix Therapeutics $700 million upfront to co-develop and co-commercialize bexobrutideg, a BTK degrader aimed at B-cell malignancies, with total deal value up to $2.3 billion. The...